Indy

Market narrative

Read the headlines around the signals.

Move between stock news, official company releases, crypto, and FX without losing the path back to ticker research.

Latest businesswire.com · 1 day ago

Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced operational updates and financial results for the second quarter of 2026. Second Quarter 2026 Financial and Business Highlights Total net sales of $29.8 million, including $24.2 million from Tru Niagen®. Direct to consumer sales on the Company's website grew by 23% year-over-year. Gross margin of 64.8%, reflecting continued strength in business mix. Net income of $1.0 million, with basic and diluted earnings per.

Read full story ↗ Research NAGE

Press releases

More recent coverage

Page 81
ADMA newsfilecorp.com · 1 day ago

ADMA BIOLOGICS DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important August 10 Deadline in Securities Class Action First Filed by the Firm - ADMA

New York, New York--(Newsfile Corp. - August 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"), of the important August 10, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased ADMA Biologics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Read source ↗
PSKY prnewswire.com · 1 day ago

PARAMOUNT REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

LOS ANGELES and NEW YORK, Aug. 4, 2026 /PRNewswire/ -- Paramount Skydance Corporation (Nasdaq: PSKY) today announced financial results for the second quarter ending June 30, 2026. The company will conduct a conference call with a live audio webcast available on Paramount's Investors homepage at ir.paramount.com beginning at 2:00 p.m.

Read source ↗
RIGL prnewswire.com · 1 day ago

Rigel Reports Second Quarter 2026 Financial Results

Second quarter 2026 total revenues of $78.7 million, including net product sales of $67.0 million and contract revenues from collaborations of $11.7 million, and net income of $17.3 million Expanded commercial portfolio with the in-license of VEPPANU™ (vepdegestrant), with U.S. commercial availability expected in mid-August Advanced R289 development program; Phase 1b study in patients with lower-risk MDS remains on track to complete enrollment in the dose expansion portion and select the recommended Phase 2 dose in the second half of 2026 Updated 2026 Outlook: Total revenues of approximately $285 to $295 million, which includes net product sales, excluding VEPPANU, of $255 to $265 million and contract revenues from collaborations of approximately $30 million Conference call and webcast scheduled today at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif.

Read source ↗
PGEN prnewswire.com · 1 day ago

Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth

PAPZIMEOS ® net revenue of $53.1 million in the second quarter of 2026, more than double the prior quarter, reflects accelerating commercial momentum and broad US adoption PAPZIMEOS revenue propelled the Company to quarterly profitability Cash, cash equivalents, and investments totaled $38.7 million as of June 30, 2026, which together with proceeds from PAPZIMEOS revenue, is expected to support cash flow break-even by the end of 2026 PAPZIMEOS patient hub enrollment reached well over 500 patients across major centers and community practices, demonstrating expanding reach and ease of administration across treatment settings FDA granted PAPZIMEOS seven-year market exclusivity, providing long-term protection against prospective competition Conference call scheduled for 4:30 PM ET today GERMANTOWN, Md., Aug. 4, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced second quarter 2026 financial results and business updates.

Read source ↗
ALGT prnewswire.com · 1 day ago

ALLEGIANT TRAVEL COMPANYSECOND QUARTER 2026 FINANCIAL RESULTS*

Second quarter 2026 GAAP loss per share of $(0.21) (1) Second quarter 2026 adjusted diluted earnings per share of $2.19 (2)(3)(4) , up 78.0 percent year-over-year * Second quarter results include the financial performance of Sun Country only from and after the date the acquisition closed on May 13, 2026 LAS VEGAS., Aug. 4, 2026 /PRNewswire/ -- Allegiant Travel Company (NASDAQ: ALGT) today reported the below financial results for second quarter 2026, as well as comparisons to the prior year.

Read source ↗
ATOM prnewswire.com · 1 day ago

Atomera Provides Second Quarter 2026 Results

LOS GATOS, Calif., Aug. 4, 2026 /PRNewswire/ -- ­­ Atomera Incorporated (NASDAQ: ATOM), a semiconductor materials and technology licensing company, today provided a corporate update and announced financial results for the second quarter ended June 30, 2026.

Read source ↗
RRR prnewswire.com · 1 day ago

Red Rock Resorts Announces Second Quarter 2026 Results

LAS VEGAS, Aug. 4, 2026 /PRNewswire/ -- Red Rock Resorts, Inc. ("Red Rock Resorts," "we" or the "Company") (NASDAQ: RRR) today reported financial results for the second quarter ended June 30, 2026. Second Quarter Results Consolidated Operations Net revenues were $510.3 million for the second quarter of 2026, a decrease of 3.0%, or $16.0 million, from $526.3 million in the same period of 2025.

Read source ↗
WYNN prnewswire.com · 1 day ago

Wynn Resorts, Limited Reports Second Quarter 2026 Results

LAS VEGAS, August 4, 2026 /PRNewswire/ -- Wynn Resorts, Limited (NASDAQ: WYNN) ("Wynn Resorts" or the "Company") today reported financial results for the second quarter ended June 30, 2026. Operating revenues were $1.86 billion for the second quarter of 2026, an increase of $119.1 million from $1.74 billion for the second quarter of 2025.

Read source ↗
RYTM globenewswire.com · 1 day ago

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chairman, President and Chief Executive Officer, and Hunter Smith, Chief Financial Officer, will participate in fireside chats at three upcoming conferences.

Read source ↗
MIST globenewswire.com · 1 day ago

Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026

MONTREAL and CHARLOTTE, N.C., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will report financial results for the second quarter ended June 30, 2026, on Wednesday, August 12, and provide a business update before the market open.

Read source ↗
DRS globenewswire.com · 1 day ago

Leonardo DRS Signs Agreement for New Brookfield, Connecticut, Facility to Support Growth of Naval Power Systems Business

ARLINGTON, Va., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Leonardo DRS, Inc. (Nasdaq: DRS) announced today that it has signed an agreement for a new facility in Brookfield, Connecticut, that will expand and consolidate operations for its Naval Power Systems business, strengthening increased throughput and support for critical U.S. Navy programs and positioning the company for future growth across the evolving nuclear energy landscape.

Read source ↗
PCRX globenewswire.com · 1 day ago

Pacira BioSciences Reports Second Quarter 2026 Financial Results

-- Continued execution of 5x30 strategy marked by solid revenue growth, durable cashflows, advancing pipeline, and high-caliber commercial partnerships -- -- Delivered second quarter total revenue of $192.4 million, representing 6 percent year-over-year growth -- -- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif.

Read source ↗
SNFCA globenewswire.com · 1 day ago

Security National Financial Corporation Announces 2026 Q2 Earnings Call

SALT LAKE CITY, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Security National Financial Corporation (NASDAQ: SNFCA) announces that on August 13, 2026, it will hold an earnings call to highlight its 2nd quarter earnings. The 30-minute call will commence at approximately 1PM (MDT) on August 13th and will include a review of its quarterly results as well as an update from the Company's three business segments.

Read source ↗
FLYW globenewswire.com · 1 day ago

Flywire Reports Second Quarter 2026 Financial Results

Second Quarter Revenue Increased 27.2% Year-over-Year Second Quarter Revenue Less Ancillary Services Increased 28.5% Year-over-Year Previous Fiscal Year 2026 FX-Neutral Revenue Less Ancillary Services growth guidance raised by 300 bps at midpoint, Adjusted EBITDA margin growth guidance raised by 25 bps at midpoint BOSTON, MA, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Flywire Corporation (Nasdaq: FLYW) (“Flywire” or the “Company”), a global payments enablement and software company, today reported financial results for its second quarter ended June 30, 2026. “Q2 was another strong quarter for Flywire, with results ahead of expectations and momentum building across all four verticals.

Read source ↗
CSWC globenewswire.com · 1 day ago

Capital Southwest Urges Shareholders to Support Authorized Shares Proposal

DALLAS, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Capital Southwest Corporation (“Capital Southwest” or the “Company”) (Nasdaq: CSWC) today encourages shareholders who have not yet voted to support the Company's proposal to increase the number of authorized shares of common stock. The Company has received substantial shareholder support for the proposal to date.

Read source ↗
SPRO globenewswire.com · 1 day ago

Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that announced that it will report its financial results for the second quarter ended June 30, 2026 on Wednesday, August 12, 2026, after market close.

Read source ↗
SKWD globenewswire.com · 1 day ago

Skyward Group Reports Second Quarter 2026 Results

HOUSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Skyward Specialty Insurance Group, Inc. (Nasdaq: SKWD) (“Skyward Group” or the “Company”) today reported second quarter 2026 results. Summary Financial Data               ($ in thousands, except per share amounts) Three months ended June 30,   Six months ended June 30, unaudited 2026   2025(1)   2026   2025(1) Managed Premiums $ 1,058,675     $ 900,849     $ 2,026,384     $ 1,710,234   Gross written premiums(2) $ 740,554     $ 653,861     $ 1,408,258     $ 1,248,431   Fee generating gross written premiums(2) $ 318,121     $ 246,988     $ 618,126     $ 461,803   Net written premiums $ 485,616     $ 339,213     $ 918,499     $ 682,484   Net income $ 49,038     $ 38,839     $ 98,769     $ 80,897   Net operating income(3) $ 59,198     $ 37,496     $ 116,091     $ 75,233   Basic earnings per share $ 1.10     $ 0.96     $ 2.22     $ 2.01   Diluted operating earnings per share $ 1.30     $ 0.89     $ 2.55     $ 1.78   Annualized ROE (4)   15.7 %     17.7 %     17.3 %     19.1 % Annualized operating ROE (5)   19.0 %     17.1 %     20.4 %     17.8 % (1) Select second quarter 2025 metrics for the Skyward Group and Apollo are presented on a pro forma basis for comparative purposes only and are not necessarily indicative of the operating results that Skyward Group would have recognized had the acquisition actually been completed on January 1, 2025.

Read source ↗
TWST businesswire.com · 1 day ago

Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST) (“Twist”), a mid-cap growth and value biotech company, today announced the commencement of an underwritten public offering of $250.0 million of shares of its common stock. In addition, Twist intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock. All of the shares of common stock to be sold in the proposed offering are being offered by.

Read source ↗
← Newer
Older →